Press release
Endometriosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 18+ Companies and 20+ Therapies | DelveInsight
Endometriosis Pipeline
Stay ahead with the latest insights! Download DelveInsight's comprehensive Endometriosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Endometriosis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Endometriosis Pipeline Report
• In May 2025, Organon and Co. conducted a Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
• In January 2025:- Organon and Co.- The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
• In January 2025:- AbbVie- A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain.
• DelveInsight's Endometriosis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Endometriosis treatment.
• The leading Endometriosis Companies such as ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
• Promising Endometriosis Pipeline Therapies such as Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
Discover how the endometriosis treatment paradigm is evolving. Access DelveInsight's in-depth Endometriosis Pipeline Analysis for a closer look at promising breakthroughs @ Endometriosis Clinical Trials and Studies- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Endometriosis Emerging Drugs Profile
• HMI-115: Hope Medicine
HMI-115 is a first-in-class monoclonal antibody drug that is developed by Hope Medicine Inc. that targets the prolactin receptor, a novel mechanism implicated in various hormone-related conditions. Designed to modulate prolactin signaling, HMI-115 holds therapeutic potential across multiple indications, including endometriosis and androgenetic alopecia. By specifically blocking the prolactin receptor, it aims to address underlying disease mechanisms without disrupting the broader hormonal balance, offering a targeted and innovative approach to treatment. Currently, the drug is in Phase II stage of its clinical development for the treatment of Endometriosis.
• Merigolix: TiumBio
TU2670 is an oral GnRH antagonist that can bind to pituitary receptors to suppress estradiol hormone. The existing treatment GnRH agonists, lowers patient comfort levels as it's in an injection form and inhibits sex hormones to the level of menopause, resulting in serious side effects such as bone loss. TU2670 is an oral GnRH antagonist that only suppresses hormone levels to the level of efficacy, improving both side effects and ease of administration by oral. In addition, being a sex hormone control mechanism, it allows for indication expansion to precocious puberty, test-tube baby, infertility treatment, etc. Currently, the drug is in Phase II stage of its development for the treatment of Endometriosis.
• SHR7280: Jiangsu HengRui Medicine Co., Ltd
SHR7280 is an orally bioavailable Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, GnRH antagonist SHR7280 competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases. Since SHR7280 reduces the occurrence of premature LH surge in females, premature ovulation is also prevented. Currently, the drug is in Phase I/II stage of its development for the treatment of Endometriosis.
The Endometriosis Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market
Explore groundbreaking therapies and clinical trials in the Endometriosis Pipeline. Access DelveInsight's detailed report now! @ New Endometriosis Drugs- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Endometriosis Companies
ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Endometriosis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Endometriosis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Endometriosis Pipeline Report
• Coverage- Global
• Endometriosis Companies- ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev, and others.
• Endometriosis Therapies- Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
• Endometriosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Endometriosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in endometriosis drug development? Find out in DelveInsight's exclusive Endometriosis Pipeline Report-access it now! @ Endometriosis Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Endometriosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometriosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. HMI-115: Hope Medicine
11. Early Stage Products (Phase I/II)
12. SHR7280: Jiangsu HengRui Medicine Co., Ltd
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Endometriosis Key Companies
17. Endometriosis Key Products
18. Endometriosis- Unmet Needs
19. Endometriosis- Market Drivers and Barriers
20. Endometriosis- Future Perspectives and Conclusion
21. Endometriosis Analyst Views
22. Endometriosis Key Companies
23. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 18+ Companies and 20+ Therapies | DelveInsight here
News-ID: 4212297 • Views: …
More Releases from DelveInsight Business Research LLP
Idiopathic Membranous Nephropathy Treatment Market Size Expected to Grow Major G …
DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore Idiopathic Membranous Nephropathy Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
…
Age-related Vision Dysfunction Treatment Market Size Expected to Grow Major Grow …
DelveInsight's "Age-related Vision Dysfunction Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the Age-related Vision Dysfunction Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and…
Warm Autoimmune Hemolytic Anemia Market Size Expected to Grow Major Growth by 20 …
DelveInsight has released a new report, "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast-2034", providing comprehensive insights into the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Explore epidemiology trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report
• On 24…
Biliary Tract Cancer Market Size Expected to Grow Major Growth by 2034, estimate …
DelveInsight's report, "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034", provides a comprehensive analysis of biliary tract cancer, including historical trends, epidemiological projections, and market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report evaluates current treatment practices, pipeline therapies, and the market share of existing and emerging interventions. It presents the current and forecasted market size for biliary tract…
More Releases for Endometriosis
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction
Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern.
Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays…
Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market: A Ke …
The Endometriosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Endometriosis Market Size and Its Estimated Growth Rate?
In recent years, there has been a swift expansion in the market size of endometriosis. This market is projected to increase from $1.4 billion…
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.01 billion In 2028 At A…
